Skip to main content

LifeCodexx to Expand Lab for Trisomy 21 Test


LifeCodexx of Konstanz, Germany, will expand its laboratory next year to provide sequencing capacity for its upcoming non-invasive prenatal diagnostic test for trisomy 21, its parent company GATC Biotech said last week.

This summer, LifeCodexx licensed a patent surrounding technology for the test from Sequenom. Under the five-year agreement, the companies will develop and launch next-gen sequencing-based tests to diagnose trisomy 21 and possibly other aneuploidies in Germany, Austria, Switzerland, and Lichtenstein first, and maybe in other countries later (CSN 8/17/2011).

In June, LifeCodexx said that it started a clinical validation study of the trisomy 21 test, involving 500 samples analyzed on the Illumina HiSeq 2000. At the time, it was planning to launch the test by the end of this year (CSN 6/29/2011).

Sequenom started offering its MaterniT21 Down syndrome test as a lab-developed test in 20 metropolitan areas in the US last month (CSN 10/19/2011).

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.